Teva Pharmaceutical Industries (TEVA) Total Liabilities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Total Liabilities for 18 consecutive years, with $31.8 billion the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities fell 1.05% year-over-year to $31.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.8 billion (down 1.05% YoY) and the FY2025 annual result came in at $32.8 billion, down 2.3% from the prior year.
• Total Liabilities eased to $31.8 billion in Q1 2026 per TEVA's latest filing, from $32.8 billion in the prior quarter.
• Over the last five years, Total Liabilities for TEVA reached as high as $36.8 billion in Q1 2022 and fell as low as $31.8 billion in Q1 2026.
• A 5-year average of $34.4 billion and a median of $34.8 billion in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities advanced 1.92% — and 2025, when it retreated 8.75%.
• Year by year, Total Liabilities stood at $35.4 billion in 2022, then slipped by 0.17% to $35.4 billion in 2023, then decreased by 4.94% to $33.6 billion in 2024, then declined by 2.3% to $32.8 billion in 2025, then dropped by 3.12% to $31.8 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $31.8 billion, $32.8 billion, and $32.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.